ALLMedicine Acne Vulgaris Center

May 28th, 2020 - Irritable bowel syndrome (IBS) is a functional gastrointestinal disease characterized by chronic abdominal pain and changes in bowel movements without underlying organic pathology. Many skin diseases have been reported to be more common in individ...

May 27th, 2020 - Topical minocycline foam 4% (Amzeeq™) is approved in the USA for the treatment of inflammatory lesions of non-nodular, moderate to severe acne vulgaris (acne) in patients aged ≥ 9 years. It was developed to minimize systemic minocycline absorption...

May 27th, 2020 - To evaluate the association of different contraceptive methods on the incidence and severity of acne. Using a de-identified commercial claims database, we performed a retrospective cohort study evaluating the incidence of clinical encounters for a...

May 26th, 2020 - Oral isotretinoin is frequently used in the treatment of young acne patients. However, knowledge levels and attitudes about this treatment have not been studied in the parents previously. We aimed to investigate the knowledge levels and concerns a...

May 26th, 2020 - Little research has compared clinician acne severity assessment with either adolescent- or parent-rated scales of acne severity or impact on quality of life (QOL). We sought to assess how adolescents and their parents perceive the severity and imp...

Oct 17th, 2019 - Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its novel AMZEEQTM (minocycline) topical foam, 4%. AMZEEQ, fo...

Oct 14th, 2019 - Acne vulgaris is the most prevalent chronic skin disease in the United States, affecting nearly 50 million people per year, mostly adolescents and young adults. Potential sequelae of acne, such as scarring, dyspigmentation, and low self-esteem, ma...

Oct 3rd, 2019 - The FDA recently approved Galderma’s topical retinoid cream, known as Aklief, for the treatment of acne vulgaris. Additionally, the company reported positive safety profiles for Aklief in two phase 3 clinical trials on acne of both the face and tr...

Nov 23rd, 2018 - Acne vulgaris, a chronic inflammatory disease of the pilosebaceous unit associated with socialisation and mental health problems, may affect more than 80% of teenagers. Isotretinoin is the only drug that targets all primary causal factors of acne;...

Nov 13th, 2018 - Acne vulgaris is an inflammatory disorder of pilosebaceous unit, which runs a chronic course and it is self-limiting. Acne vulgaris is triggered by Propionibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrost...

May 28th, 2020 - Irritable bowel syndrome (IBS) is a functional gastrointestinal disease characterized by chronic abdominal pain and changes in bowel movements without underlying organic pathology. Many skin diseases have been reported to be more common in individ...

May 27th, 2020 - Topical minocycline foam 4% (Amzeeq™) is approved in the USA for the treatment of inflammatory lesions of non-nodular, moderate to severe acne vulgaris (acne) in patients aged ≥ 9 years. It was developed to minimize systemic minocycline absorption...

May 27th, 2020 - To evaluate the association of different contraceptive methods on the incidence and severity of acne. Using a de-identified commercial claims database, we performed a retrospective cohort study evaluating the incidence of clinical encounters for a...

May 26th, 2020 - Oral isotretinoin is frequently used in the treatment of young acne patients. However, knowledge levels and attitudes about this treatment have not been studied in the parents previously. We aimed to investigate the knowledge levels and concerns a...

May 26th, 2020 - Little research has compared clinician acne severity assessment with either adolescent- or parent-rated scales of acne severity or impact on quality of life (QOL). We sought to assess how adolescents and their parents perceive the severity and imp...

Feb 26th, 2020 - Aklief (trifarotene) Trifarotene is an agonist of retinoic acid receptors (RARs), with particular activity at the gamma subtype of RAR. Stimulation of RARs results in modulation of target genes that are associated with various processes, including...

Feb 20th, 2020 - When the first issue of Cutis was published in February 1965: Alopecia was featured on the cover Eugene F. Traub, MD, was Chief Editor, and John T.

Feb 12th, 2020 - Arazlo Lotion Approved for Acne Vulgaris Ortho Dermatologics announces US Food and Drug Administration approval of Arazlo (tazarotene) Lotion 0. 045% for the topical treatment of acne vulgaris in patients 9 years and older.

Dec 18th, 2019 - The US Food and Drug Administration (FDA) has approved tazarotene lotion 0.045% (Arazlo, Ortho Dermatologics) to treat acne vulgaris in individuals aged 9 years and older. Arazlo is the first tazarotene acne treatment available in lotion form, and...

Nov 11th, 2019 - Aklief Cream Topical Retinoid Approved for Acne Vulgaris Galderma Laboratories, LP, announces US Food and Drug Administration approval of Aklief (trifarotene) Cream 0. 005% for the treatment of acne vulgaris in patients 9 years and older.